Forbion closes third life sciences fund
Forbion Capital Partners closed its third life sciences fund, Forbion Capital Fund III, at EUR 183 million ($208.2 million).
The fund's LPs include the European Investment Fund, Dutch Venture Initiative, KfW, Charles River Laboratories International Inc. (NYSE:CRL), Knight Therapeutics Inc. (TSX:GUD) and undisclosed regional investment agencies, pension funds, insurance companies and European family offices. ...